Amylyx Pharmaceuticals AMLX Stock
Amylyx Pharmaceuticals Price Chart
Amylyx Pharmaceuticals AMLX Financial and Trading Overview
| Amylyx Pharmaceuticals stock price | 14.98 USD |
| Previous Close | 24.89 USD |
| Open | 24.77 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1000 |
| Day's Range | 24.51 - 24.99 USD |
| 52 Week Range | 15.8 - 41.93 USD |
| Volume | 971.95K USD |
| Avg. Volume | 941.95K USD |
| Market Cap | 1.66B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.79 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 49.17 USD |
AMLX Valuation Measures
| Enterprise Value | 1.33B USD |
| Trailing P/E | N/A |
| Forward P/E | 8.5379305 |
| PEG Ratio (5 yr expected) | 0.54 |
| Price/Sales (ttm) | 17.759083 |
| Price/Book (mrq) | 4.710807 |
| Enterprise Value/Revenue | 14.223 |
| Enterprise Value/EBITDA | -8.599 |
Trading Information
Amylyx Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 38.86% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 41.93 USD |
| 52 Week Low | 15.8 USD |
| 50-Day Moving Average | 27.75 USD |
| 200-Day Moving Average | 32.29 USD |
AMLX Share Statistics
| Avg. Volume (3 month) | 941.95K USD |
| Avg. Daily Volume (10-Days) | 742.75K USD |
| Shares Outstanding | 67.18M |
| Float | 40.05M |
| Short Ratio | 7.76 |
| % Held by Insiders | 23.46% |
| % Held by Institutions | 81.98% |
| Shares Short | 8.8M |
| Short % of Float | 17.50% |
| Short % of Shares Outstanding | 13.10% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -159.039% |
| Operating Margin (ttm) | -166.11% |
| Gross Margin | -9.43% |
| EBITDA Margin | -165.41% |
Management Effectiveness
| Return on Assets (ttm) | -28.49% |
| Return on Equity (ttm) | -50.18% |
Income Statement
| Revenue (ttm) | 93.66M USD |
| Revenue Per Share (ttm) | 1.5 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -74213000 USD |
| EBITDA | -154924000 USD |
| Net Income Avi to Common (ttm) | -148954000 USD |
| Diluted EPS (ttm) | -2.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 345.67M USD |
| Total Cash Per Share (mrq) | 5.15 USD |
| Total Debt (mrq) | 5.79M USD |
| Total Debt/Equity (mrq) | 1.64 USD |
| Current Ratio (mrq) | 7.537 |
| Book Value Per Share (mrq) | 5.256 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -144308992 USD |
| Levered Free Cash Flow (ttm) | -84066496 USD |
Profile of Amylyx Pharmaceuticals
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 43 Thorndike Street |
| ZIP | 02141 |
| Phone | 617 682 0917 |
| Website | https://amylyx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 296 |
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Q&A For Amylyx Pharmaceuticals Stock
What is a current AMLX stock price?
Amylyx Pharmaceuticals AMLX stock price today per share is 14.98 USD.
How to purchase Amylyx Pharmaceuticals stock?
You can buy AMLX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amylyx Pharmaceuticals?
The stock symbol or ticker of Amylyx Pharmaceuticals is AMLX.
Which industry does the Amylyx Pharmaceuticals company belong to?
The Amylyx Pharmaceuticals industry is Biotechnology.
How many shares does Amylyx Pharmaceuticals have in circulation?
The max supply of Amylyx Pharmaceuticals shares is 109.82M.
What is Amylyx Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Amylyx Pharmaceuticals PE Ratio is now.
What was Amylyx Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Amylyx Pharmaceuticals EPS is -1.79 USD over the trailing 12 months.
Which sector does the Amylyx Pharmaceuticals company belong to?
The Amylyx Pharmaceuticals sector is Healthcare.
Amylyx Pharmaceuticals AMLX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23365.69 USD — |
+0.65
|
4B USD — | 23250.51 USD — | 23365.8 USD — | — - | 4B USD — |
| US Tech Global Select Market Com NQGS | 11454.84 USD — |
+0.64
|
— — | 11398.12 USD — | 11454.97 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech US 700 Small Cap Index NQUS700SC | 2621.04 USD — |
+0.42
|
— — | 2614.16 USD — | 2624.1 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 3476.4 USD — |
+0.87
|
— — | 3456.33 USD — | 3478.36 USD — | — - | — — |
| US Tech Biotechnology NBI | 5818.03 USD — |
+0.08
|
— — | 5790.69 USD — | 5821.69 USD — | — - | — — |
| US Tech Health Care IXHC | 1210.8 USD — |
+0.06
|
— — | 1205.13 USD — | 1211.61 USD — | — - | — — |
- {{ link.label }} {{link}}


